Monitor progress on Psyga acquisition and shareholder vote. If the deal closes by June 30, the delisting risk recedes; failure to close would trigger immediate delisting proceedings. The $8M market cap leaves limited upside even if successful.
Price Chart
Executive Summary
Nasdaq Hearing Panel granted XTL Biopharmaceuticals an exception to continue listing on Nasdaq until June 30, 2026, conditional on completing the acquisition of Psyga Bio Ltd. and securing up to $1.5M in private placement funding. The company remains at risk of delisting if the transaction fails or compliance conditions are not met.
Key Facts
- Nasdaq granted continued listing exception until June 30, 2026, conditioned on closing the Psyga Bio acquisition.
- Company secured commitment of up to $1.5M private placement, contingent on closing the Psyga Transaction.
- Company was deemed a 'public shell' under Nasdaq Rule 5101 and also faced bid price deficiency (now cured via reverse stock split).
- Psyga Transaction remains subject to shareholder approval and other conditions; no assurance of closing.
Financial Impact
Up to $1.5M private placement upon closing of Psyga acquisition; acquisition price not disclosed.
Risk Factors
- Psyga acquisition may not close by June 30 deadline, triggering delisting.
- Company remains classified as a 'public shell' with limited operational revenue.
- Shareholder approval may not be obtained.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-053067 |
| Document: 0001213900-26-053067-index-headers.html | 0001213900-26-053067 |
| Document: 0001213900-26-053067-index.html | 0001213900-26-053067 |
| Document: 0001213900-26-053067.txt | 0001213900-26-053067 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 6-K | $1.91 | awaiting T+60 | — | $1.81 (−5.24%) |
Jun 30, 2026 16w ago | 20-F | $2.49 $2.41 | ▲ +3.21% | ▲ +6.08% | $1.81 (+27.31%) |
Jun 29, 2026 17w ago | 6-K | $2.73 $2.20 | ▼ −19.41% | ▼ −22.23% | $1.81 (−33.70%) |
May 22, 2026 22w ago | 6-K | $2.38 $2.98 | ▼ −25.21% | ▼ −22.49% | $1.81 (+23.95%) |
May 7, 2026 24w ago | 6-K | $2.67 $2.86 | ▲ +7.15% | ▲ +3.31% | $1.81 (−32.21%) |
Apr 29, 2026 25w ago | 6-K | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.81 (−49.16%) |
Apr 29, 2026 25w ago | Press Release | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.81 (−49.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers